Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Esophageal Cancer clinical trials
Every US clinical trial registered for Esophageal Cancer — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
132 US clinical trials · 63 currently recruiting
The research picture
Esophageal Cancer has 132 registered US clinical trials, 63 of them open to new participants right now — about 48% of the total.
- 63
- recruiting participants now
- 48%
- of trials open to enrollment
- 8
- in Phase 3–4 (later-stage)
- 10
- top sponsor: Memorial Sloan Kettering Cancer Center
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
Integrated Cancer Repository for Cancer Research
University of Nebraska
NCT02012699
Esophageal Cancer Risk Registry
University of Pittsburgh
NCT00260585
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Adela
NCT05366881
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Vanderbilt University Medical Center
NCT00899626
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
University of Colorado, Denver
NCT02634645
Retrospective Review of Esophageal Cancer at MSKCC
Memorial Sloan Kettering Cancer Center
NCT05706558
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
University of Pittsburgh
NCT00260559
EsophaCap for the Detection of Early Esophageal Carcinoma
Johns Hopkins University
NCT04214119
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
NCT07431281
Pan-tumor MRD Study
Paradigm Health
NCT06605404
Mayo Clinic Upper Digestive Disease Survey
Mayo Clinic
NCT02530983
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT06172478
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
University of Colorado, Denver
NCT00900419
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
University of Missouri-Columbia
NCT02838836
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
NCT03526835
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06238479
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT07223424
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune
NCT05983432
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT05581004
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06465069
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
University of Colorado, Denver
NCT05517811
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
University of Missouri-Columbia
NCT03551951
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT07090499
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
University of California, Davis
NCT06101277
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
Resilience and Equity in Aging, Cancer, and Health (REACH)
Dana-Farber Cancer Institute
NCT04674267
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology
NCT03556228
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Merck Sharp & Dohme
NCT06445972
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
SOFIE
NCT07217704
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Phrontline Biopharma
NCT07181473
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
Northwestern University
NCT05056051
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NCT06263088
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT06695845
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Merck Sharp & Dohme
NCT06469944
Serial MRI Scans During Radiation Therapy
Dana-Farber Cancer Institute
NCT04188535
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies
NCT06047379
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06239194
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT06710756
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
NCT04354064
DESTINY-PANTUMOUR04
AstraZeneca
NCT07124000
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Stanford University
NCT01048281
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
M.D. Anderson Cancer Center
NCT06181656
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Lumicell
NCT02584244
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
M.D. Anderson Cancer Center
NCT06414902
Registry for Esophageal and Gastroesophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
NCT06558786
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
John Waters
NCT07039526
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
Medical College of Wisconsin
NCT06906887
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT06123338
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT03740256
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
NCT05187182
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Zumutor Biologics
NCT06451497
Volume Outcome Relationships and Effects
Methodist Health System
NCT06343597
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Lantheus Medical Imaging
NCT06298916
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
University of Michigan Rogel Cancer Center
NCT05183126
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
University of Pittsburgh
NCT06872515
Exercise Prehabilitation for Locoregional Esophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT06430346
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT07001592
Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy
University of Utah
NCT04846309
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Cedars-Sinai Medical Center
NCT07124351
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT06673329
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Memorial Sloan Kettering Cancer Center
NCT00582647
Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial
M.D. Anderson Cancer Center
NCT01512589
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05215574
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM CT
NCT04044859
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co.
NCT05438420
BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy
OHSU Knight Cancer Institute
NCT06335966
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics
NCT05864144
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure
NCT05572684
Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging
Memorial Sloan Kettering Cancer Center
NCT04400292
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
Duke University
NCT03403465
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Adaptimmune
NCT03132922
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05311618
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT05565417
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Legend Biotech USA
NCT05539430
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
NCT03174275
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03044613
Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer
Abramson Cancer Center at Penn Medicine
NCT02213497
Proton Beam Therapy in the Treatment of Esophageal Cancer
Washington University School of Medicine
NCT03482791
Cryotherapy for Locally Advanced Esophageal Cancer
Hunter Holmes Mcguire Veteran Affairs Medical Center
NCT04248582
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Washington University School of Medicine
NCT04046575
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
NCT05480384
Genetic and Environmental Risk Factors Related to Esophageal Cancer
Massachusetts General Hospital
NCT01035398
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
Labcorp Corporation of America Holdings
NCT05697198
Evaluations of Alcohol Warning Labels
University of Connecticut
NCT06129487
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
NCT00052910
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
NCT02349412
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Alliance for Clinical Trials in Oncology
NCT01333033
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
Dana-Farber Cancer Institute
NCT00831571
Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery
M.D. Anderson Cancer Center
NCT00505024
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
Covenant Health Cancer Center
NCT05369234
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
SWOG Cancer Research Network
NCT00086996
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Eastern Cooperative Oncology Group
NCT00033657
Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer
Case Comprehensive Cancer Center
NCT00258323
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
Memorial Sloan Kettering Cancer Center
NCT00002930
S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
SWOG Cancer Research Network
NCT00012363
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
Dana-Farber Cancer Institute
NCT00165464
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 49 |
| Phase 2 | 35 |
| Phase 3 | 5 |
| Phase 4 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Esophageal Cancer Trial Landscape
ClinicalTrials.gov lists 132 US studies indexed under Esophageal Cancer, and 63 of those are currently open to recruitment — roughly 48% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Esophageal Cancer shows 8 late-stage studies (Phase 3 and Phase 4 combined) alongside 84 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Esophageal Cancer is led by Memorial Sloan Kettering Cancer Center with 10 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 100 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Esophageal Cancer?
PlainTrial tracks 132 US clinical trials for Esophageal Cancer, of which 63 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Esophageal Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.